Innovative Cellular Therapeutics Holdings Limited 13D and 13G filings for Lyell Immunopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-06-18 4:31 pm Purchase | 2026-05-18 | 13G | LYELL IMMUNOPHARMA INC LYEL | Innovative Cellular Therapeutics Holdings Limited | 3,000,000 12.300% | 1,100,000 (+57.89%) | Filing |
| 2025-11-13 5:04 pm Purchase | 2025-11-06 | 13G | LYELL IMMUNOPHARMA INC LYEL | Innovative Cellular Therapeutics Holdings Limited | 1,900,000 9.800% | 1,900,000 (New Position) | Filing |